Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Chardan Capital themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Alnylam Pharmaceuticals (ALNY) Buy Rating Reaffirmed at Chardan Capital theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a report issued on Monday morning. A number of other analysts have also commented on the stock. BMO Capital Markets restated an outperform rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in […]
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM, revenues increased 7%First quarter 2024 Dupixent® global net sales increased 24% to.